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CLINICAL PROBLEM
A 50-year-old woman who was new to the dental office sought treatment because of a chief
complaint of pain in her jaw and teeth “for many years.” During a period of several years,
she had seen many dentists who had adjusted her occlusion and restored most of her molars
in an attempt to eliminate her pain. However, her facial pain condition did not improve with
this treatment approach. Her previous dentist made an oral appliance and told her that there
was nothing else he could do for her. She reported that the soreness in her jaw and her
headaches had worsened lately. The patient’s medical history included constant headaches,
irritable bowel syndrome, vulvar vestibulitis syndrome and fibromyalgia (FM). Is there an
association between her chronic facial pain and these other widespread pain conditions?
EXPLANATION
Three distinct patterns of pain distribution—localized, regional and widespread—generally
are recognized.1,2 Various psychological and general health factors have been identified as
risk factors for the development of chronic widespread pain (CWP). These include poor
general health, sleep disturbance, fatigue and high levels of psychological distress.3,4 In a
prospective study, Von Korff and colleagues5 found that the presence of one pain condition
at baseline was associated with a fourfold increased risk of developing a temporomandibular
disorder (TMD). In addition, Aggarwal and colleagues6 reported that one of the strongest
predictors of chronic TMD pain was a history of having had CWP.
The results of various studies have shown that chronic facial pain often is comorbid with
other pain conditions including FM,7 headaches,8 vulvar vestibulitis syndrome (also known
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as vulvodynia),9 spinal pain10 and low back pain.11 The results of a prospective longitudinal
study showed that participants who developed TMD reported having had a higher
experience of joint, back, chest and menstrual pain at baseline.12 They also were more likely
to be experiencing other pains at the time of TMD onset compared with participants who did
not develop TMD. These findings suggest that, for certain patients, regional and widespread
chronic pain conditions represent overlapping conditions and should be considered part of a
continuum rather than distinct entities with separate etiologies.
FM represents one end of the CWP continuum.13 Study investigators evaluating the overlap
between FM and TMD reported that 35 to 97 percent of patients with FM had signs and
symptoms of TMD, while the prevalence of FM in patients with TMD was an estimated 10
to 52 percent.14–16 These percentages vary widely owing to different inclusion criteria.
Similarities reported in the two conditions included typical clinical pain reports, common
symptoms such as sleep difficulty and fatigue, and psycho - pathology such as depression
and anxiety disorders; again, this suggests that TMD pain in patients with FM may be an
extension of the CWP rather than a separate entity.
Diatchenko and colleagues17 hypothesized that, irrespective of the peripheral pain location,
chronic pain probably is regulated within the body in a similar fashion. These authors
proposed that idiopathic pain disorders share common denominators, including exposure to
certain environmental events, elevated levels of psychological distress, a tendency toward
pain amplification and genetic predisposition.17 These pathways of vulnerability are
interactive, and as a group they influence the patient’s risk of experiencing pain onset and
persistence.
Several lines of evidence indicate that alterations in central pain processing play an
important role in the onset of CWP, the exacerbation of CWP or both. In an experimental
setting, patients with TMD demonstrated abnormal temporal summation (that is, enhanced
pain intensity in response to repetitive noxious stimulation), and this enhanced temporal
summation usually is not limited to the area of clinical pain.18 Functional abnormalities of
the hypothalamic-pituitary-adrenal axis, which is the major physiological stress response
system in the body, are another hallmark of chronic pain conditions. Light and colleagues19
conducted a double-masked, crossover, placebo-controlled trial and reported that
propranolol, a β-adrenergic antagonist, reduced the total number of painful sites and pain
ratings in patients with TMD and FM. Taken together, the data from these studies suggest
generalized hyperexcitability of the central nociceptive system in patients with chronic pain.
The results of human genetic studies revealed associations between certain genetic
polymorphisms and the development of chronic pain syndromes.20,21 When coupled with
environmental triggers, these genetic factors contribute to enhanced pain perception,
psychological dysfunction and an increased risk of onset and persistence of TMD and
related idiopathic pain disorders. Diatchenko and colleagues22 identified three genetic
variants (haplotypes) of the gene encoding catecholamine-O-methyltransferase designated as
low-, average- and high-pain sensitivity. The presence of even a single low-pain–sensitivity
haplotype reduces by 2.3 times the risk of developing TMD.
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Increased awareness of the overlap between chronic TMD and comorbid pain conditions
likely will result in improved diagnoses and more effective pain management.23 Patients
with TMD symptoms often are treated within a narrow dental paradigm while clinicians
ignore coexisting pain conditions, resulting in treatment failure and perpetuation of the
problem. Raphael and Marbach24 conducted a randomized, controlled clinical trial, the
results of which showed that patients with TMD and widespread pain did not experience
improvement with oral appliance therapy, whereas those with only local TMD pain did
experience improvement. Researchers in future studies need to address the impact of these
pathways of vulnerability on the effectiveness of the various treatment modalities for
chronic TMD and comorbid pain disorders.
Various simple self-administered questionnaires are available to aid the general dentist in
assessing possible comorbid pain conditions. The Fibromyalgia Rapid Screening Tool is a
sixitem inventory requiring “yes” or “no” responses; it has a sensitivity of 90.5 percent and a
specificity of 85.7 percent in the detection of FM.25 The ID Migraine screener is a three-
item questionnaire also requiring “yes” or “no” responses; it has a positive predictive value
of 93 percent.26 Practitioners also can assess associated symptoms such as depression and
anxiety, somatization, insomnia and fatigue by means of various validated short
questionnaires, such as the Beck Depression Inventory27 and the State-Trait Anxiety
Inventory.28
CONCLUSION
An urgent need exists for a multifaceted approach to the treatment of TMD that is based not
only on its etiology but also on the presence or absence of comorbid conditions. According
to a recently revised policy statement of the American Association for Dental Research,29
“unless there are specific and justifiable indications to the contrary, treatment of TMD
patients initially should be based on the use of conservative, reversible and evidence-based
therapeutic modalities.” These include patient education and self-management, cognitive
behavioral therapy, pharmacotherapy, physical therapy and use of orthopedic appliances. In
patients with comorbid conditions, however, referral to a multidisciplinary pain clinic for
assessment and treatment almost always will produce a better outcome for all concerned.
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